Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277
Recruiting
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: UMass Memorial Medical Center - University Campus - Oncology, Worcester, Massachusetts
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Register for Updates
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Boston, Massachusetts
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
NCT06181240
Recruiting
The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Coronary Artery Disease, Coronary Artery Calcification
Register for Updates
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT06172127
Recruiting
DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer (MBC) patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: HER2-positive Breast Cancer
Register for Updates
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
NCT06138561
Recruiting
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at ri... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
Register for Updates
Texting to Reduce Human Immunodeficiency Virus (HIV) Risk
NCT06088277
Recruiting
This is a 3-year study to test the efficacy of a text message-based intervention program. Dental patients at 4 community health centers (n= 266) will be randomized to receive either text messages (TMs) regarding HIV prevention or TMs regarding overall wellness. Prior to enrolling the 266 participants, the investigators will conduct a feasibility pilot (n=20) to test the TM delivery as well as all study procedures. For both the pilot and the randomized clinical trial (RCT), recruitment will be co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: South End Community Health Center, Boston, Massachusetts
Conditions: HIV Infections
Register for Updates
The Actuate-CBC Study
NCT05917652
Recruiting
The study team will use implementation science to accelerate the uptake of teleconsultationfor burn patients by 1) examining the relationships between clinician perceptions of acceptability, feasibility, intention to use, and actual use of burn teleconsultation 2) identifying the optimal process for burn teleconsultation and the barriers and facilitators for its use during a crisis or prolonged care situation, and 3) designing and testing the effectiveness of a specific, tailored burn teleconsul... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Massachusetts General Hospital Sumner Redstone Burn Center, Boston, Massachusetts
Conditions: Telemedicine
Register for Updates
Gravitas Feeding Tube System Placement Validation in Neonates
NCT05914064
Recruiting
The purpose of this study is to validate the Gravitas Feeding Tube System Placement Algorithm for NICU patients and to evaluate the safety and effectiveness of the Gravitas Feeding Tube in the neonate population for the administration of nutrition, fluids and medications.
Gender:
ALL
Ages:
Between 0 weeks and 18 weeks
Trial Updated:
07/25/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Nasogastric Tube
Register for Updates
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
NCT05287451
Recruiting
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Harvard Cancer Center, Boston, Massachusetts
Conditions: Ovarian Cancer, Fallopian Tube Cancer
Register for Updates
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
NCT05019716
Recruiting
This phase I/II trial tests the safety, side effects, and best dose of a new combination of drugs, ZEN003694, cisplatin, and etoposide in treating patients with NUT carcinoma (phase I), and identifies whether this combination therapy works to shrink tumor in these patients (phase II). Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certa... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Metastatic NUT Carcinoma, Unresectable NUT Carcinoma, Advanced NUT Carcinoma
Register for Updates
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
NCT04635111
Recruiting
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Hepatotoxicity, Tenosynovial Giant Cell Tumor
Register for Updates
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
NCT06987890
Recruiting
National guidelines recommend that older adults with cancer undergo a special health assessment before starting cancer treatment. This type of assessment evaluates physical function, nutrition, social support, psychological well-being, medical conditions (both cancer-related and non-cancer-related), and cognitive function. The results can help doctors make better treatment decisions and determine whether additional support services-such as nutrition counseling, physical therapy, or social work-w... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/24/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Lung Cancer (NSCLC), Geriatric Assessment, Stereotactic Body Radiation Therapy (SBRT)
Register for Updates